Grace Therapeutics Inc
For the period ended Mar 31, 2025. Filed Jun 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jun 23, 2025
GRCE$1.87+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| March 31, 2025 | March 31, 2024 | |
|---|---|---|
| (Expressed in thousands except share data) | $ | $ |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 22,133 | 23,005 |
| Receivables | 126 | 722 |
| Prepaid expenses | 453 | 283 |
| Total current assets | 22,712 | 24,010 |
| Equipment, net | 15 | 24 |
| Intangible assets | 41,128 | 41,128 |
| Goodwill | 8,138 | 8,138 |
| Total assets | 71,993 | 73,300 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Trade and other payables | 1,930 | 1,684 |
| Total current liabilities | 1,930 | 1,684 |
| Derivative warrant liabilities | 1,141 | 4,359 |
| Deferred tax liability | 2,312 | 5,514 |
| Total liabilities | 5,383 | 11,557 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share; 10,000,000 authorized, none issued and outstanding as of March 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value per share; 100,000,000 authorized; 13,718,106 and 9,399,404 shares issued and outstanding as of March 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 293,334 | 278,899 |
| Accumulated other comprehensive loss | (6,038) | (6,038) |
| Accumulated deficit | (220,687) | (211,119) |
| Total stockholders' equity | 66,610 | 61,743 |
| Total liabilities and stockholders’ equity | 71,993 | 73,300 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.